Navigation Links
oxaliplatin in Medical News

Chemotherapy combination outcomes differ for aged, younger colon cancer patients

...O, Fla.--The combination of chemotherapies 5FU and oxaliplatin compared to 5FU alone after surgery for colon canc...y 30, 3 p.m. ET (Level 2, West Hall D2). Adding oxaliplatin to chemotherapy treatment with 5FU reduces the ris...s. Patients under 70 who were treated with 5FU and oxaliplatin had improved disease-free survival, with the addit...

NCCN Announces Updates to Pancreatic Adenocarcinoma Guidelines

... Dr. Tempero also recommended fluorinated pyrimidine-based therapy with oxaliplatin (Eloxatin(R), sanofi-aventis) as a second-line option for patients with adv...selected gemcitabine combinations followed by a fluorinated pyrimidine plus oxaliplatin is the standard of care." Of all the gastrointestinal malignancies, pa...

Use of Avastin and Erbitux in the Adjuvant Setting and Launches of Emerging Agents Will Drive the Colorectal Cancer Drug Market to $7.8 Billion in 2017

...l take market share away from some currently-available therapies, including oxaliplatin (Sanofi-Aventis's Eloxatin/Eloxatine and Yakult Honsha's Elplat). The expected entrance of generic oxaliplatin in the U.S. colorectal cancer market in late 2009 and in Japan in 2013 will...

Adding a Cancer Drug May Make Matters Worse

...uximab (Erbitux) to a standard three-drug regimen of bevacizumab (Avastin), oxaliplatin (Eloxatin) and capecitabine (Xeloda), Punt said. Each drug works in a different way. Capecitabine and oxaliplatin kill cancer cells directly, whereas bevacizumab inhibits vascular endotheli...

Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin

...l is evaluating picoplatin as a neuropathy-sparing replacement for oxaliplatin for the first-line treatment of metastatic CRC in 101 patients who...bination with 5-fluorouracil and leucovorin (the FOLPI regimen) to oxaliplatin given in combination with 5-fluorouracil and leucovorin in the FOL...

Also in the Dec. 30 JNCI

...okinetics May Explain Differences in Cisplatin and oxaliplatin Ototoxicity More cisplatin enters the inner ear...tment in humans can lead to hearing problems while oxaliplatin rarely does. The amount of cisplatin a patient ...e induced by the drug, referred to as ototoxicity. oxaliplatin is not frequently associated with the problem, des...

New platinum-phosphate compounds kill ovarian cancer cells

...ctive, it works best during the early stages of the disease, and some patients develop a resistance to it. Two drugs introduced later, carboplatin and oxaliplatin (which is used for colorectal cancer), overcame some of those problems, but their potency can harm the immune system of patients, said Bose, who has b...

Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update

...latin, given once every four weeks in the FOLPI regimen, was associated with less frequent and less severe neurotoxicity than the FOLFOX regimen where oxaliplatin has shown treatment-limiting neurotoxicity. These data support further development of picoplatin for this indication. -- Presented expanded and upda...

Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008

...vel of anti-cancer activity of ProLindac in a heavily-pretreated patient population compares favorably to previously published results of single agent oxaliplatin in patients that had less pretreatment. These promising efficacy results were obtained without significant toxicity or other significant side-effects....

Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update

...and leucovorin in the FOLPI regimen may have similar anti-tumor activity to oxaliplatin in combination with 5-fluorouracil and leucovorin in the FOLFOX regimen, wh...ed with substantial neurotoxicity related to increasing cumulative doses of oxaliplatin at greater than 800 mg/m2. In addition, nephrotoxicities and ototoxicities ...
oxaliplatin in Medical Technology

New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer

-Growing Body of Data Supports XELOX as Effective Alternative to Standard of Care- NUTLEY, N.J., Jan. 13 /PRNewswire-FirstCall/ -- Overall survival results from a 14-month follow-up of the international, Phase III NO16966 study confirm that oral Xeloda(R) plus oxaliplatin (XELOX) is comp...

Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

... Currently, there are seven approved drugs for patients with metastatic colorectal cancer: 5-FU, capecitabine (Xeloda(R)), irinotecan (Camptosar(R)), oxaliplatin (Eloxatin(R)), bevacizumab (Avastin(R)), cetuximab (Erbitux(R)), and panitumumab (Vectibix(R)). Depending on the stage of the cancer, two or more of ...

Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

... Currently, there are seven approved drugs for patients with metastatic colorectal cancer: 5-FU, capecitabine (Xeloda(R)), irinotecan (Camptosar(R)), oxaliplatin (Eloxatin(R)), bevacizumab (Avastin(R)), cetuximab (Erbitux(R)), and panitumumab (Vectibix(R)). Depending on the stage of the cancer, two or more of ...

Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer

... Picoplatin as a Neuropathy-Sparing Alternative to oxaliplatin for First-Line Treatment of Colorectal Cancer - ... with the use of picoplatin in FOLPI compared with oxaliplatin in FOLFOX (p<0.0019). "Oxaliplatin give...orectal cancer with comparable clinical benefit to oxaliplatin but with significantly less neurotoxicity." ...

Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update

...iard initiated a randomized, controlled, proof-of-concept Phase 2 trial in November 2007 to evaluate picoplatin as a neuropathy-sparing alternative to oxaliplatin for the first-line treatment of metastatic CRC. Patient enrollment was completed in May 2008. Oral Picoplatin I...

Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update

...I regimen, was associated with less frequent and less severe neurotoxicity than the FOLFOX (5-fluorouracil, leucovorin and oxaliplatin) regimen, where oxaliplatin has shown treatment-limiting neurotoxicity. Results also continue to indicate that both FOLPI and FOLFOX regimens have similar anti-tumor activity as ...

Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results

...id Nowotnik, Access' Senior Vice President R&D. "The DACH platinum activity level seen benchmarked favorably with published studies of monotherapy oxaliplatin in similar but less heavily pre-treated patient populations. Having achieved the recommended dose for future combination studies, we look forward to m...

Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer

...nt of multiple solid tumor indications. "The comparison of picoplatin and oxaliplatin in combination with 5-fluorouracil and leucovorin has provided encouraging ...(Grade 3 or 4), as is commonly seen in metastatic CRC patients treated with oxaliplatin in combination with 5-fluorouracil and leucovorin as part of the FOLFOX reg...

Data Confirm Avastin(R) Helps Patients With Metastatic Colorectal Cancer Live Even Longer

...tive and also well tolerated for CRC patients with yet further chemotherapy combinations, Xeloda (capecitabine) and irinotecan (XELIRI) and Xeloda and oxaliplatin (XELOX). This data reinforces that Avastin is first choice for the treatment of patients with CRC and that it can be used in combination with any chem...

New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients

...roject (NSABP) C-08, a Randomized Hall D1 Phase III Study of Modified 5-Fluorouracil (5-FU)/Leucovorin and oxaliplatin (mFOLFOX6) With or Without Bevacizumab in the Adjuvant Treatment of Patients With Stage II/III Colon Cancer ...
oxaliplatin in Medical Dictionary

Injection

...up to date Chlordiazepoxide Injection information - part of the Drugs.com trusted medication database. Read more about the prescription drug oxaliplatin - INJECTION . ... home > oxaliplatin- injection index > oxaliplatin- injection , eloxatin drug monograph ... Consumer information about ...
oxaliplatin in Biological News

Trial seeks 'genetic fingerprint' for predicting drug effectiveness

...rapy. Participants will receive daily doses of the platinum-containing drug oxaliplatin (ox-AL-ih-plah-tin, marketed as Eloxatin) for six to eight weeks. Approved by the Food and Drug Administration, oxaliplatin is currently used to treat advanced colorectal cancer. Studies have shown t...
oxaliplatin in Biological Technology

The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.

... by sanofi-aventis U.S. to be used for scientific purposes as defined and overseen by the NIH. The donation of three drugs - docetaxel (Taxotere(R)), oxaliplatin injection (Eloxatin(R)) and enoxaparin sodium injection (Lovenox(R)) - will be made over the course of one year. "At a time when the costs of...

Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update

...sults continue to support picoplatin as a neuropathy-sparing alternative to oxaliplatin with similar anti-tumor activity as assessed by PFS and disease control mea...urotoxicities with the use of picoplatin in the FOLPI regimen compared with oxaliplatin in the FOLFOX regimen (p<0.0019). Castration-Resist...

Sanofi-aventis Announces Second Quarter 2009 Results

...a of the lower legs, is complete. The Phase III study evaluating xaliproden in the prevention of severe peripheral sensory neuropathy induced by oxaliplatin in patients with metastatic colorectal cancer did not attain its primary end point. It was therefore decided to discontinue development of this produc...

Hospira Receives Favorable Court Decision on Eloxatin(R)

...ortly. Hospira's version of Eloxatin, which goes by the generic name oxaliplatin injection, will be one of the first generic versions available in the Unite...ice president, Specialty Pharmaceuticals, Hospira. "The launch of Hospira's oxaliplatin injection will provide a high-quality, lower-cost alternative to patients, ...

Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer

... picoplatin as a neuropathy-sparing alternative to oxaliplatin for the first-line treatment of metastatic CRC. P...d with less frequent and severe neurotoxicity than oxaliplatin given in combination with 5-fluorouracil and leuco...ents treated with the FOLFOX regimen at cumulative oxaliplatin doses above 800 mg/m squared. In addition, none of...

Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer

...rt Picoplatin as Neuropathy-Sparing Alternative to oxaliplatin in First-Line Colorectal Cancer Treatment - S...h less frequent and less severe neurotoxicity than oxaliplatin given in combination with 5-fluorouracil and leuco...in may provide a neuropathy-sparing alternative to oxaliplatin in patients with advanced colorectal cancer. I'm e...

Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer

...rin (FOLPI), is associated with less frequent and severe neurotoxicity than oxaliplatin given in combination with 5-fluorouracil and leucovorin in the modified FOL...ation with bi-weekly 5-fluorouracil and leucovorin (the FOLPI regimen) with oxaliplatin given in combination with 5-fluorouracil and leucovorin in the FOLFOX regim...

Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update

...higher), as is commonly seen in metastatic CRC patients treated with oxaliplatin as part of the FOLFOX regimen. Current National Comprehensive Cancer...ll-dose 5-fluorouracil and leucovorin dosing in the FOLPI regimen to oxaliplatin in combination with 5-fluorouracil and leucovorin in the modified FO...

First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs

...ng, ovarian, colorectal, and testicular cancers. Three important monoplatinates are in common use including, carboplatin for lung and ovarian cancers, oxaliplatin for colorectal cancer, and cisplatin for testicular, lung and ovarian cancers. Global sales of platinum based drugs exceeded $1.5 Billion in 2006. Ab...
Other Tags
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... With the FCPX LUT Soft pack from ... LUT is a Lookup Table that contains a mathematical formula for modifying an image. The ... comes with 60 soft CUBE LUT files. , FCPX LUT Soft requires Final Cut ...
(Date:8/31/2015)... ... August 31, 2015 , ... Diablo Publications (DP), ... it has officially launched a new website and company identity ( diablopublications.com) . ... more closely aligned with the company’s strategic vision for growth and expansion over ...
(Date:8/31/2015)... ... August 31, 2015 , ... Dad Phil, ... ribbon-cutting ceremony on Aug. 26, generously hosted by the Collinsville Chamber of Commerce, ... AdvantaClean’s National Call Center and website since Aug. 17. , The Greens have ...
(Date:8/31/2015)... ... August 31, 2015 , ... Physicians’ ... Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® meeting, is seeking ... 6 in New York City. The annual legacy meeting uses a variety of ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... be at a greater risk for injury, potentially because they are more susceptible ... Pittsburgh Graduate School of Public Health analysis discovered. , The research, published ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios, FCPX Plugin Developer, Releases FCPX LUT Soft 2Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Ribbon Cutting Launches AdvantaClean of Madison County 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 3Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 4Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 3
(Date:8/5/2015)... 2015 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends and ... recognition is forecast to reach US$ 2,671.8 Mn by ... surveillance systems by civil and government agencies. This is ... terrorist activities across the globe that would elevate the ...
(Date:8/4/2015)... , Aug. 04, 2015 ... ) has announced the addition of the ... Software, and Service), Sub-Segment (Computer Forensics, Network ... Tool Types, Service, Vertical and Region - ... their offering. By Component (Hardware, ...
(Date:8/3/2015)... 3, 2015 Synaptics, Inc. (Nasdaq: SYNA ... announced that members of the executive management team will ... Global Technology Leadership Forum on Tuesday, August 11, 2015 ... held at the Sonnenalp Resort in Vail, ... include forward-looking information. An audio webcast of the event ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
Other Contents